REG - Abbott Laboratories - ABT 2Q16 Earnings Announcement <Origin Href="QuoteRef">ABT.N</Origin> - Part 2
- Part 2: For the preceding part double click ID:nRST7645Ea
655 772 1,427
Diluted Earnings per Share from Continuing Operations $0.44 $0.52 $0.96
Specified items reflect intangible amortization expense of $289 million, the
impact of the foreign exchange loss in Venezuela of $477 million, and other
expenses of $270 million, primarily associated with acquisitions, including
bridge facility fees, and charges related to cost reduction initiatives and
other expenses, partially offset by a net tax benefit of approximately $145
million as a result of the resolution of various tax positions from prior
years.
1H15
As Specified As % to
Reported Items Adjusted Sales
(GAAP)
Intangible Amortization $307 ($307) --
Gross Margin 5,461 371 $5,832 57.9%
R&D 658 (22) 636 6.3%
SG&A 3,464 (109) 3,355 33.3%
Other (income) expense, net (284) 282 (2)
Earnings from Continuing Operations before taxes 1,639 220 1,859
Taxes on Earnings from Continuing Operations 324 30 354
Net Earnings from Continuing Operations 1,315 190 1,505
Diluted Earnings per Share from Continuing Operations $0.87 $0.12 $0.99
Specified items reflect intangible amortization expense of $307 million and
other expenses of $200 million, primarily associated with cost reduction
initiatives and acquisitions, partially offset by a gain on the sale of a
portion of Abbott's position in Mylan stock of $207 million and a decrease in
the fair value of contingent consideration related to a business acquisition.
RECONCILIATION OF TAX RATE FOR CONTINUING OPERATIONS
A reconciliation of the second-quarter tax rates for continuing operations for
2016 and 2015 is shown below:
2Q16
($ in millions) Pre-Tax Taxes on Tax
Income Earnings Rate
As reported (GAAP) $715 $116 16.2%
Specified items 283 70
Excluding specified items $998 $186 18.6%
2Q15
($ in millions) Pre-Tax Taxes on Tax
Income Earnings Rate
As reported (GAAP) $986 $200 20.2%
Specified items (15) (15)
Excluding specified items $971 $185 19.0%
A reconciliation of the year-to-date tax rates for continuing operations for
2016 and 2015 is shown below:
1H16
($ in millions) Pre-Tax Taxes on Tax
Income Earnings Rate
As reported (GAAP) $717 $62 8.6% 1)
Specified items 1,036 264
Excluding specified items $1,753 $326 18.6%
1H15
($ in millions) Pre-Tax Taxes on Tax
Income Earnings Rate
As reported (GAAP) $1,639 $324 19.7%
Specified items 220 30
Excluding specified items $1,859 $354 19.0%
1) Reported tax rate on a GAAP basis for 2016 includes the impact of a net tax benefit of approximately $145 million as a result of the resolution of various tax positions from prior years, partially offset by the unfavorable impact of non-deductible foreign exchange losses related to Venezuela.
CONTACT: Abbott Financial: Scott Leinenweber, (224) 668-0791; Michael Comilla,
(224) 668-1872; Jeffrey Byrne, (224) 668-8808; Abbott Media: Darcy Ross, (224)
667-3655; Elissa Maurer, (224) 668-3309
This information is provided by RNS
The company news service from the London Stock ExchangeRecent news on Abbott Laboratories
See all newsREG - Takeover Panel - Disclosure Table
AnnouncementREG - Takeover Panel - Disclosure Table
AnnouncementREG - Takeover Panel - Disclosure Table
AnnouncementREG - Takeover Panel - Disclosure Table
AnnouncementREG - Takeover Panel - Disclosure Table
Announcement